|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
CA2066428C
(en)
|
1989-09-08 |
2000-11-28 |
Bert Vogelstein |
Structural alterations of the egf receptor gene in human gliomas
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
DE69303494T2
(de)
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DK0659439T3
(da)
|
1993-12-24 |
2002-01-14 |
Merck Patent Gmbh |
Immunkonjugater
|
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
HU216142B
(hu)
|
1994-07-21 |
1999-04-28 |
Akzo Nobel N.V. |
Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
JPH11507535A
(ja)
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
EP0836605B1
(en)
|
1995-07-06 |
2002-02-06 |
Novartis AG |
Pyrrolopyrimidines and processes for the preparation thereof
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
JP3370340B2
(ja)
|
1996-04-12 |
2003-01-27 |
ワーナー―ランバート・コンパニー |
チロシンキナーゼの不可逆的阻害剤
|
|
DE69716916T2
(de)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd., Greenford |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
ATE549918T1
(de)
|
1996-12-03 |
2012-04-15 |
Amgen Fremont Inc |
Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
ES2201484T3
(es)
|
1997-05-06 |
2004-03-16 |
Wyeth Holdings Corporation |
Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
|
|
CA2293829C
(en)
|
1997-06-24 |
2011-06-14 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
DE69840412D1
(de)
|
1997-10-31 |
2009-02-12 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
|
NZ503991A
(en)
|
1997-11-06 |
2001-11-30 |
American Cyanamid Co |
Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
|
ES2188254T3
(es)
|
1998-11-19 |
2003-06-16 |
Warner Lambert Co |
N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Kyowa Kirin Co., Ltd. |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
|
ES2274823T3
(es)
|
1999-12-29 |
2007-06-01 |
Immunogen, Inc. |
Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
DK2314686T4
(da)
|
2000-10-06 |
2023-08-21 |
Kyowa Kirin Co Ltd |
Celler, der danner antistofsammensætninger
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
IL155977A0
(en)
|
2000-11-30 |
2003-12-23 |
Medarex Inc |
Transgenic transchromosomal rodents for making human antibodies
|
|
NZ581474A
(en)
|
2001-08-03 |
2011-04-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
EP1502603A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
|
|
AU2003236017B2
(en)
|
2002-04-09 |
2009-03-26 |
Kyowa Kirin Co., Ltd. |
Drug containing antibody composition
|
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
PT1692182E
(pt)
|
2003-11-05 |
2010-05-13 |
Roche Glycart Ag |
Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
|
|
EP3434275A1
(en)
|
2003-11-06 |
2019-01-30 |
Seattle Genetics, Inc. |
Assay for cancer cells based on the use of auristatin conjugates with antibodies
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
KR20140024270A
(ko)
|
2010-12-30 |
2014-02-28 |
파운데이션 메디신 인코포레이티드 |
종양 샘플의 다유전자 분석의 최적화
|
|
WO2012106175A1
(en)
|
2011-02-02 |
2012-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
|
|
CA2854832C
(en)
|
2011-11-07 |
2023-05-23 |
Ingenuity Systems, Inc. |
Methods and systems for identification of causal genomic variants
|
|
US20140287937A1
(en)
|
2013-02-21 |
2014-09-25 |
Toma Biosciences, Inc. |
Methods for assessing cancer
|
|
CN113337604A
(zh)
|
2013-03-15 |
2021-09-03 |
莱兰斯坦福初级大学评议会 |
循环核酸肿瘤标志物的鉴别和用途
|
|
WO2014151006A2
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
EP4524972A3
(en)
|
2013-05-10 |
2025-06-18 |
Foundation Medicine, Inc. |
Analysis of genetic variants
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
SG10201805674YA
(en)
*
|
2014-01-02 |
2018-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
AU2015210886A1
(en)
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
EP3134436A4
(en)
|
2014-04-25 |
2017-12-27 |
Memorial Sloan Kettering Cancer Center |
Treatment of h-ras-driven tumors
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
WO2016018481A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of California |
Network based stratification of tumor mutations
|
|
EP4098278A1
(en)
|
2014-11-13 |
2022-12-07 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
WO2016089873A1
(en)
|
2014-12-02 |
2016-06-09 |
Celgene Corporation |
Combination therapies
|
|
EP3265079A4
(en)
|
2015-03-03 |
2019-01-02 |
Caris MPI, Inc. |
Molecular profiling for cancer
|
|
WO2017040960A1
(en)
|
2015-09-04 |
2017-03-09 |
The Brigham And Women's Hospital, Inc. |
Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
|
|
JP6930992B2
(ja)
|
2016-02-29 |
2021-09-01 |
ファウンデーション・メディシン・インコーポレイテッド |
腫瘍変異負荷を評価するための方法及びシステム
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
CN109476731A
(zh)
|
2016-02-29 |
2019-03-15 |
基础医药有限公司 |
治疗癌症的方法
|
|
EP3433373B1
(en)
|
2016-03-22 |
2022-01-12 |
Myriad Women's Health, Inc. |
Combinatorial dna screening
|
|
EP3523451A1
(en)
*
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|